FIBROBIOLOGICS INC (FBLG) Stock Price & Overview

NASDAQ:FBLG • US31573L1052

Current stock price

0.3124 USD
-0.03 (-8.14%)
At close:
0.3175 USD
+0.01 (+1.63%)
After Hours:

The current stock price of FBLG is 0.3124 USD. Today FBLG is down by -8.14%. In the past month the price increased by 26.99%. In the past year, price decreased by -69.37%.

FBLG Key Statistics

52-Week Range0.2201 - 1.53
Current FBLG stock price positioned within its 52-week range.
1-Month Range0.2402 - 0.4799
Current FBLG stock price positioned within its 1-month range.
Market Cap
21.115M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.42
Dividend Yield
N/A

FBLG Stock Performance

Today
-8.14%
1 Week
-28.18%
1 Month
+26.99%
3 Months
-20.49%
Longer-term
6 Months -42.45%
1 Year -69.37%
2 Years -97.11%
3 Years N/A
5 Years N/A
10 Years N/A

FBLG Stock Chart

FIBROBIOLOGICS INC / FBLG Daily stock chart

FBLG Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to FBLG. When comparing the yearly performance of all stocks, FBLG is a bad performer in the overall market: 93.18% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

FBLG Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to FBLG. The financial health of FBLG is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

FBLG Earnings

Next Earnings DateMay 12, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported-$0.03
Revenue Reported
EPS Surprise 66.39%
Revenue Surprise %

FBLG Forecast & Estimates

9 analysts have analysed FBLG and the average price target is 7.14 USD. This implies a price increase of 2185.53% is expected in the next year compared to the current price of 0.3124.


Analysts
Analysts82.22
Price Target7.14 (2185.53%)
EPS Next Y40.5%
Revenue Next YearN/A

FBLG Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

FBLG Financial Highlights

Over the last trailing twelve months FBLG reported a non-GAAP Earnings per Share(EPS) of -0.42. The EPS decreased by -26.92% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-18.65M
Industry RankSector Rank
PM (TTM) N/A
ROA -193.85%
ROE -302.89%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%66.67%
Sales Q2Q%N/A
EPS 1Y (TTM)-26.92%
Revenue 1Y (TTM)N/A

FBLG Ownership

Ownership
Inst Owners6.63%
Shares67.59M
Float55.70M
Ins Owners9.31%
Short Float %1.15%
Short Ratio0.34

FBLG Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC14.8398.492B
AMGN AMGEN INC16.04198.265B
GILD GILEAD SCIENCES INC16.4180.267B
VRTX VERTEX PHARMACEUTICALS INC24.21121.459B
REGN REGENERON PHARMACEUTICALS15.9578.932B
ALNY ALNYLAM PHARMACEUTICALS INC42.0142.071B
INSM INSMED INC N/A30.073B
BIIB BIOGEN INC11.2927.136B
NTRA NATERA INC N/A26.973B
UTHR UNITED THERAPEUTICS CORP17.9523.353B
MRNA MODERNA INC N/A21.086B
EXAS EXACT SCIENCES CORP340.7419.713B
RVMD REVOLUTION MEDICINES INC N/A18.84B

About FBLG

Company Profile

FBLG logo image FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 15 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.

Company Info

IPO: 2024-01-31

FIBROBIOLOGICS INC

455 E. Medical Center Blvd, Suite 300

Houston TEXAS US

Employees: 13

FBLG Company Website

FBLG Investor Relations

Phone: 12816715150

FIBROBIOLOGICS INC / FBLG FAQ

Can you describe the business of FIBROBIOLOGICS INC?

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 15 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.


What is the stock price of FIBROBIOLOGICS INC today?

The current stock price of FBLG is 0.3124 USD. The price decreased by -8.14% in the last trading session.


Does FBLG stock pay dividends?

FBLG does not pay a dividend.


What is the ChartMill technical and fundamental rating of FBLG stock?

FBLG has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Is FIBROBIOLOGICS INC (FBLG) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FBLG.


What is the employee count for FBLG stock?

FIBROBIOLOGICS INC (FBLG) currently has 13 employees.


What is FIBROBIOLOGICS INC worth?

FIBROBIOLOGICS INC (FBLG) has a market capitalization of 21.12M USD. This makes FBLG a Nano Cap stock.